ArticleClinical and translational medicine2018

Does ALK-rearrangement predict favorable response to the therapy of bevacizumab plus pemetrexed in advanced non-small-cell lung cancer? Case report and literature review.

Zhichao Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.